Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK Plc delivers strong Q1 2025 with profit and Specialty Medicines growth

GSK PLC reports strong Q1 2025 results, driven by Specialty Medicines growth and significant R&D investments, highlighting confidence in future performance...

Nuformix secures positive EMA opinion for orphan drug status in IPF

Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF)...

Aptamer licences Optimer binders for swine vaccines

Aptamer Group plc has secured a significant global licensing deal with the University of Glasgow, advancing synthetic binders for vaccines in swine health...

One Health Group accelerates expansion amid soaring demand

One Health Group is transforming healthcare with impressive growth and a commitment to tackling NHS waiting times, solidifying its role as a trusted provider...

Advancing RSV research with the New RSV-B London strain

Discover hVIVO's groundbreaking RSV-B London strain, a pivotal advancement in respiratory virus research, enhancing vaccine and antiviral development for RSV...

AstraZeneca Plc reports revenue up 10%, strong pipeline progress

AstraZeneca Plc's Q1 2025 results reveal strong growth and a focus on pipeline delivery, setting the stage for ambitious goals leading to 2030...

Nuformix updates Registered Office and Company Secretary

Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary...

Aptamer to present Optimer® liver targeting data at 2025 ASGCT

Aptamer Group plc is set to unveil groundbreaking data on its Optimer® delivery vehicle for fibrotic liver disease at the 2025 ASGCT Annual Meeting...

Cizzle Bio expands into Caribbean with first contract, secures early royalties

Cizzle Biotechnology announces significant strides in early lung cancer detection through its partner's first Caribbean contract, boosting its biomarker test rollout...

One Health Group delivers 20% revenue surge after AIM debut

One Health Group's first trading update since its AIM listing reveals over 20% revenue growth, highlighting its strong market position and promising future in healthcare...

Professor Sir Chris Evans on EDX Medical’s new testicular cancer test (AQSE:EDX)

EDX Medical Group is set to revolutionise testicular cancer detection with a groundbreaking test boasting over 90% sensitivity...

Viral innovation drives health preparedness and market opportunity

As concerns over public health rise, understanding influenza's impact on healthcare evolves into a key opportunity for savvy investors in biotech and vaccine development...

Aptamer Group publishes new Corporate Presentation and Investor Factsheet

Aptamer Group plc has released a new corporate presentation and investor factsheet, showcasing its strategic growth, operational progress, and financial performance in the life science industry...

One Health Group FY25 revenue up 22%, record NHS demand

One Health Group plc's trading update highlights impressive growth in NHS-funded procedures. Discover their revenue surge, new contracts, and plans for expansion...

EDX launches groundbreaking blood test for testicular cancer

Introducing the TC100 by EDX Medical: a revolutionary, non-invasive blood test transforming testicular cancer detection with AI precision and unmatched accuracy...

How patient behaviour transformed first-in-human dosing

Navigating first-in-human trials requires precision. Learn how integrating real-world patient insights, like cannabis use, enhances drug development for schizophrenia...

DCC Plc to sell healthcare unit for £1.05 billion

DCC plc has agreed to sell its healthcare division to HealthCo Investment for £1.05 billion, streamlining operations and enhancing shareholder value...

AstraZeneca Plc Enhertu trial hits key PFS goal

The DESTINY-Breast09 Phase III trial of Enhertu marks a breakthrough for HER2-positive metastatic breast cancer, showcasing superior efficacy over traditional therapies...

HUTCHMED completes Savolitinib trial enrollment

HUTCHMED has successfully completed patient enrollment for a Phase II trial of savolitinib, targeting gastric cancer patients with MET amplification...

Spine care surge positions One Health for investor growth

Discover One Health Group's innovative approach to back and spine care, blending advanced surgeries with non-invasive therapies for optimal patient outcomes...
Search

Funds

Health

GSK Plc delivers strong Q1 2025 with profit and Specialty Medicines growth

GSK PLC reports strong Q1 2025 results, driven by Specialty Medicines growth and significant R&D investments, highlighting confidence in future performance...

Nuformix secures positive EMA opinion for orphan drug status in IPF

Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF)...

Aptamer licences Optimer binders for swine vaccines

Aptamer Group plc has secured a significant global licensing deal with the University of Glasgow, advancing synthetic binders for vaccines in swine health...

One Health Group accelerates expansion amid soaring demand

One Health Group is transforming healthcare with impressive growth and a commitment to tackling NHS waiting times, solidifying its role as a trusted provider...

Advancing RSV research with the New RSV-B London strain

Discover hVIVO's groundbreaking RSV-B London strain, a pivotal advancement in respiratory virus research, enhancing vaccine and antiviral development for RSV...

AstraZeneca Plc reports revenue up 10%, strong pipeline progress

AstraZeneca Plc's Q1 2025 results reveal strong growth and a focus on pipeline delivery, setting the stage for ambitious goals leading to 2030...

Nuformix updates Registered Office and Company Secretary

Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary...

Aptamer to present Optimer® liver targeting data at 2025 ASGCT

Aptamer Group plc is set to unveil groundbreaking data on its Optimer® delivery vehicle for fibrotic liver disease at the 2025 ASGCT Annual Meeting...

Cizzle Bio expands into Caribbean with first contract, secures early royalties

Cizzle Biotechnology announces significant strides in early lung cancer detection through its partner's first Caribbean contract, boosting its biomarker test rollout...

One Health Group delivers 20% revenue surge after AIM debut

One Health Group's first trading update since its AIM listing reveals over 20% revenue growth, highlighting its strong market position and promising future in healthcare...

Professor Sir Chris Evans on EDX Medical’s new testicular cancer test (AQSE:EDX)

EDX Medical Group is set to revolutionise testicular cancer detection with a groundbreaking test boasting over 90% sensitivity...

Viral innovation drives health preparedness and market opportunity

As concerns over public health rise, understanding influenza's impact on healthcare evolves into a key opportunity for savvy investors in biotech and vaccine development...

Aptamer Group publishes new Corporate Presentation and Investor Factsheet

Aptamer Group plc has released a new corporate presentation and investor factsheet, showcasing its strategic growth, operational progress, and financial performance in the life science industry...

One Health Group FY25 revenue up 22%, record NHS demand

One Health Group plc's trading update highlights impressive growth in NHS-funded procedures. Discover their revenue surge, new contracts, and plans for expansion...

EDX launches groundbreaking blood test for testicular cancer

Introducing the TC100 by EDX Medical: a revolutionary, non-invasive blood test transforming testicular cancer detection with AI precision and unmatched accuracy...

How patient behaviour transformed first-in-human dosing

Navigating first-in-human trials requires precision. Learn how integrating real-world patient insights, like cannabis use, enhances drug development for schizophrenia...

DCC Plc to sell healthcare unit for £1.05 billion

DCC plc has agreed to sell its healthcare division to HealthCo Investment for £1.05 billion, streamlining operations and enhancing shareholder value...

AstraZeneca Plc Enhertu trial hits key PFS goal

The DESTINY-Breast09 Phase III trial of Enhertu marks a breakthrough for HER2-positive metastatic breast cancer, showcasing superior efficacy over traditional therapies...

HUTCHMED completes Savolitinib trial enrollment

HUTCHMED has successfully completed patient enrollment for a Phase II trial of savolitinib, targeting gastric cancer patients with MET amplification...

Spine care surge positions One Health for investor growth

Discover One Health Group's innovative approach to back and spine care, blending advanced surgeries with non-invasive therapies for optimal patient outcomes...
Search

Funds

Health

FTSE 100

Funds